Living Cell Technologies Ltd. (AU:1AI) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Living Cell Technologies Ltd. is set to launch its AlgoraeOS artificial intelligence platform, which will predict drug combinations for diseases by analyzing vast medical data. The platform has already shown promising results in pre-clinical studies, particularly with AI-116 for dementia outperforming standard treatments in cell studies. Additionally, the company is advancing pre-clinical studies for AI-168, a new drug candidate targeting cardiovascular diseases.
For further insights into AU:1AI stock, check out TipRanks’ Stock Analysis page.
